A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究連絡先のバックアップ
- 名前:Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
- 電話番号:888-662-6728
- メール:global-roche-genentech-trials@gene.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
- Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
- Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study
Exclusion Criteria:
- Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- Chronic liver disease unless considered stable for >6 months
- Acute liver disease
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
- Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
- Total bilirubin greater than 1.5 × ULN
- A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment
Note: Other protocol-defined inclusion/exclusion criteria may apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Fenebrutinib
Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study. |
Fenebrutinib will be administered as per the schedule specified in the protocol.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of Participants With Adverse Events (AEs)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change in Expanded Disability Status Scale (EDSS) Score Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in 9-hole Peg Test (9-HPT) Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Timed 25-foot Walk Test (T25FWT) Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Modified cCDP24
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of T1 Hypointense MRI Lesions
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T2 Lesions
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T1 Hypointense Lesions
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Brain Volume
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in MSIS-29 Psychological Scale Over Time
時間枠:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Trials、Hoffmann-La Roche
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CN45787
- 2026-526037-26-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。